Bayer Must Allow Cancer Generic In India, Court Rules

Law360, New York (March 12, 2012, 6:55 PM EDT) -- An Indian patent court has for the first time forced a pharmaceutical company to open up the generic market for a costly cancer drug, ordering Bayer AG to permit a cheaper version of its cancer treatment Nexavar, in a precedential ruling made public Monday.

The decision by the Indian Controller General of Patents, Designs and Trademarks allows Indian generic-drug maker Natco Pharma Ltd. to make and sell generic Nexavar, also called sorafenib, in exchange for a quarterly royalty to Bayer of 6 percent of net sales....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.